抗肿瘤药物处方审核专家共识——肝癌

李国辉, 郝志英, 陈喆, 柴丽敏, 周海燕, 刘广宣, 戴媛媛, 刘江, 黄红兵, 徐珽, 黄萍, 翟青, 王晨, 刘玉国, 张文周, 刘向红, 蒋刚, 曹俊岭, 王丽霞, 刘国强, 孙言才, 姜明燕, 吕永宁, 卢晓阳, 刘茂柏, 梁宁生, 宋燕青, 李朋梅, 董梅, 姚敦武, 李桂茹, 孔树佳, 谢瑞祥, 王建华, 魏青, 贾乐川, 李玫, 孟珺, 曹舫, 张雯, 孙永琨, 鄢丹, 白在先, 戴助, 赫捷

中国药学杂志 ›› 2019, Vol. 54 ›› Issue (18) : 1539-1542.

PDF(1172 KB)
PDF(1172 KB)
中国药学杂志 ›› 2019, Vol. 54 ›› Issue (18) : 1539-1542. DOI: 10.11669/cpj.2019.18.017
·论著·

抗肿瘤药物处方审核专家共识——肝癌

  • 李国辉1, 郝志英2, 陈喆1, 柴丽敏2, 周海燕1, 刘广宣3, 戴媛媛1, 刘江4, 黄红兵5, 徐珽6, 黄萍7, 翟青8, 王晨9, 刘玉国10, 张文周11, 刘向红12, 蒋刚13, 曹俊岭14, 王丽霞15, 刘国强16, 孙言才17, 姜明燕18, 吕永宁19, 卢晓阳20, 刘茂柏21, 梁宁生22, 宋燕青23, 李朋梅24, 董梅25, 姚敦武26, 李桂茹27, 孔树佳28, 谢瑞祥29, 王建华30, 魏青31, 贾乐川32, 李玫33, 孟珺34, 曹舫35, 张雯1, 孙永琨1, 鄢丹36, 白在先37, 戴助38, 赫捷1*
作者信息 +
文章历史 +

关键词

抗肿瘤 / 处方 / 共识 / 肝癌

引用本文

导出引用
李国辉, 郝志英, 陈喆, 柴丽敏, 周海燕, 刘广宣, 戴媛媛, 刘江, 黄红兵, 徐珽, 黄萍, 翟青, 王晨, 刘玉国, 张文周, 刘向红, 蒋刚, 曹俊岭, 王丽霞, 刘国强, 孙言才, 姜明燕, 吕永宁, 卢晓阳, 刘茂柏, 梁宁生, 宋燕青, 李朋梅, 董梅, 姚敦武, 李桂茹, 孔树佳, 谢瑞祥, 王建华, 魏青, 贾乐川, 李玫, 孟珺, 曹舫, 张雯, 孙永琨, 鄢丹, 白在先, 戴助, 赫捷. 抗肿瘤药物处方审核专家共识——肝癌[J]. 中国药学杂志, 2019, 54(18): 1539-1542 https://doi.org/10.11669/cpj.2019.18.017
中图分类号: R979.1   

参考文献

[1]CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI:10.3322/caac.21338.
[2]Chinese Society of Clinical Oncology (CSCO) Guidelines for Diagnosis and Treatment of Primary Hepatocellular Carcinoma(中国临床肿瘤学会原发性肝癌诊疗指南)[M]. Beijing: Peaple’s Medical Publishing House, 2018.
[3]Bureau of Medical Administration, National Health and Family Planning Comission of the PRC. Standardization of diagnosis and treatment for hepatocellular carcinoma (2017 edition) [J]. Chin J Digest Surg(中华消化外科杂志), 2017,16(7): 635-647.
[4]National Comprehensive Cancer Network. Hepatobiliary Cancer (version 1.2019)[S/OL]. http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.
[5]QIN S, BAI Y, LIM H Y, et al. Randomized,multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28):3501-3508.
[6]National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Antiemensis, Version 3. 2018. https://www. nccn. org/professionals/physician_gls/pdf/antiemesis.pdf.
[7]LLOVET J M, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4):378-390.
[8]CHENG A L, KANG Y K, CHEN Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1):25-34.
[9]KUDO M, FINN R S, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 noninferioritytrial[J].Lancet, 2018, 391(10126):1163-1173.
[10]BRUIX J, QIN S, MERLE P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064):56-66.
[11]EL-KHOUEIRY A B, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088):2492-2502.
[12]ZHU A X, FINN R S, EDELINE J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a nonrandomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7):940-952.

基金

中国医学科学院医学与健康科技创新工程项目(2016-I2M-1-001;2017-I2M-2-003)
PDF(1172 KB)

Accesses

Citation

Detail

段落导航
相关文章

/